- Home
- PTY vs HCM Comparison
PTY vs HCM Comparison
Compare PTY & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTY
- HCM
- Stock Information
- Founded
- PTY 2002
- HCM 2000
- Country
- PTY United States
- HCM Hong Kong
- Employees
- PTY N/A
- HCM N/A
- Industry
- PTY Investment Managers
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- PTY Finance
- HCM Health Care
- Exchange
- PTY Nasdaq
- HCM Nasdaq
- Market Cap
- PTY 2.2B
- HCM 2.3B
- IPO Year
- PTY N/A
- HCM N/A
- Fundamental
- Price
- PTY $14.74
- HCM $16.11
- Analyst Decision
- PTY
- HCM Hold
- Analyst Count
- PTY 0
- HCM 1
- Target Price
- PTY N/A
- HCM $19.00
- AVG Volume (30 Days)
- PTY 550.4K
- HCM 73.5K
- Earning Date
- PTY 01-01-0001
- HCM 03-19-2025
- Dividend Yield
- PTY 9.65%
- HCM N/A
- EPS Growth
- PTY N/A
- HCM N/A
- EPS
- PTY N/A
- HCM N/A
- Revenue
- PTY N/A
- HCM $610,806,000.00
- Revenue This Year
- PTY N/A
- HCM N/A
- Revenue Next Year
- PTY N/A
- HCM $15.89
- P/E Ratio
- PTY N/A
- HCM N/A
- Revenue Growth
- PTY N/A
- HCM N/A
- 52 Week Low
- PTY $11.92
- HCM $12.84
- 52 Week High
- PTY $14.88
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- PTY 60.38
- HCM 68.69
- Support Level
- PTY $14.62
- HCM $13.58
- Resistance Level
- PTY $14.87
- HCM $13.96
- Average True Range (ATR)
- PTY 0.07
- HCM 0.31
- MACD
- PTY -0.01
- HCM 0.34
- Stochastic Oscillator
- PTY 51.85
- HCM 89.84
About PTY Pimco Corporate & Income Opportunity Fund
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.